InnoTherapy Inc (246960) - Total Assets
Based on the latest financial reports, InnoTherapy Inc (246960) holds total assets worth ₩75.35 Billion KRW (≈ $51.06 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 246960 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
InnoTherapy Inc - Total Assets Trend (2015–2024)
This chart illustrates how InnoTherapy Inc's total assets have evolved over time, based on quarterly financial data. See InnoTherapy Inc shareholders equity for net asset value and shareholders' equity analysis.
InnoTherapy Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
InnoTherapy Inc's total assets of ₩75.35 Billion consist of 22.7% current assets and 77.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩937.09 Million | 3.9% |
| Accounts Receivable | ₩2.11 Billion | 8.8% |
| Inventory | ₩597.10 Million | 2.5% |
| Property, Plant & Equipment | ₩9.79 Billion | 40.7% |
| Intangible Assets | ₩4.69 Billion | 19.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how InnoTherapy Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of InnoTherapy Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: InnoTherapy Inc's current assets represent 22.7% of total assets in 2024, a decrease from 59.3% in 2015.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2024, down from 29.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 1.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 40.7% of total assets.
InnoTherapy Inc Competitors by Total Assets
Key competitors of InnoTherapy Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Bactiguard Holding AB (publ)
ST:BACTI-B
|
Sweden | Skr537.34 Million |
|
Sequana Medical NV
BR:SEQUA
|
Belgium | €14.57 Million |
InnoTherapy Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.98 | 3.72 | 6.60 |
| Quick Ratio | 0.92 | 3.40 | 6.42 |
| Cash Ratio | 0.00 | 0.42 | 0.00 |
| Working Capital | ₩-464.20 Million | ₩4.67 Billion | ₩4.68 Billion |
InnoTherapy Inc - Advanced Valuation Insights
This section examines the relationship between InnoTherapy Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.74 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -20.2% |
| Total Assets | ₩24.06 Billion |
| Market Capitalization | $9.43 Million USD |
Valuation Analysis
Below Book Valuation: The market values InnoTherapy Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: InnoTherapy Inc's assets decreased by 20.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for InnoTherapy Inc (2015–2024)
The table below shows the annual total assets of InnoTherapy Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩24.06 Billion ≈ $16.30 Million |
-20.23% |
| 2023-12-31 | ₩30.16 Billion ≈ $20.44 Million |
-2.13% |
| 2022-12-31 | ₩30.81 Billion ≈ $20.88 Million |
-3.35% |
| 2021-12-31 | ₩31.88 Billion ≈ $21.61 Million |
+83.75% |
| 2020-12-31 | ₩17.35 Billion ≈ $11.76 Million |
+0.69% |
| 2019-12-31 | ₩17.23 Billion ≈ $11.68 Million |
+54.19% |
| 2018-12-31 | ₩11.18 Billion ≈ $7.57 Million |
+165.86% |
| 2017-12-31 | ₩4.20 Billion ≈ $2.85 Million |
-40.22% |
| 2016-12-31 | ₩7.03 Billion ≈ $4.77 Million |
-13.29% |
| 2015-12-31 | ₩8.11 Billion ≈ $5.50 Million |
-- |
About InnoTherapy Inc
SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasi… Read more